Active	Status	Sponsor type	Region	Phase	Filter
5 Active 1 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Mandalà, Mario
KEYNOTE-D18, NCT05155254 / 2021-004594-32: IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)	Active, not recruiting	3	407	Europe, US, RoW	IO102-IO103, Pembrolizumab	IO Biotech, Syneos Health, Merck Sharp & Dohme LLC	Metastatic Melanoma, Unresectable Melanoma	07/25	09/27
USZ-STRIKE, NCT05522660: Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer	Recruiting	3	190	Europe	Stereotactic radiosurgery, Immune checkpoint inhibitor, standard of care treatment	ETOP IBCSG Partners Foundation, USZ Foundation	Non-Small Cell Lung Cancer, Melanoma	01/26	12/26
NEO-CESQ, NCT04632433 / 2019-001469-34: Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell Carcinoma	Active, not recruiting	2	25	Europe	Cemiplimab	Fondazione Melanoma Onlus	Cutaneous Squamous Cell Carcinoma	02/23	02/26
EBIN, NCT03235245 / 2017-002887-42: Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib	Active, not recruiting	2	271	Europe	Nivolumab + Ipilimumab, Encorafenib + Binimetinib	European Organisation for Research and Treatment of Cancer - EORTC	Unresectable Stage III Melanoma, Stage IV Melanoma	10/23	01/27
ALFAOMEGA, NCT04120935: Master Observational Trial	Recruiting	N/A	3000	Europe	Observation	IFOM ETS - The AIRC Institute of Molecular Oncology	Colorectal Cancer	07/25	12/25